Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aprea Therapeutics, Inc. | SVP, Chief Financial Officer | Common Stock | 145 K | $534 K | $3.68 | Jul 28, 2022 | Direct |
AGILE THERAPEUTICS INC | Chief Financial Officer | Common Stock | 20.1 K | $17.1 K | $0.85 | Oct 3, 2023 | Direct |
Aprea Therapeutics, Inc. | SVP, Chief Financial Officer | Stock Option (right to Buy) | 89.2 K | Jul 28, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AGRX | AGILE THERAPEUTICS INC | Oct 3, 2023 | 1 | $0 | 4 | Oct 4, 2023 | Chief Financial Officer |
AGRX | AGILE THERAPEUTICS INC | Aug 16, 2023 | 0 | $0 | 3 | Aug 25, 2023 | Chief Financial Officer |
APRE | Aprea Therapeutics, Inc. | Jul 28, 2022 | 2 | $0 | 4 | Aug 1, 2022 | SVP, Chief Financial Officer |
APRE | Aprea Therapeutics, Inc. | Jun 3, 2022 | 1 | -$28.4 K | 4 | Jun 7, 2022 | SVP, Chief Financial Officer, Director |
APRE | Aprea Therapeutics, Inc. | Mar 10, 2022 | 2 | $0 | 4 | Mar 14, 2022 | SVP, Chief Financial Officer, Director |
APRE | Aprea Therapeutics, Inc. | Feb 25, 2022 | 1 | -$25.8 K | 4 | Mar 1, 2022 | SVP, Chief Financial Officer |
APRE | Aprea Therapeutics, Inc. | Aug 25, 2021 | 1 | -$30 K | 4 | Aug 27, 2021 | SVP, Chief Financial Officer |